stockrowAbbott Laboratories
ABT Healthcare Medical Devices
Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.
- Revenue
- +14.5%
- EPS
- −43.6%
- Free cash flow
- +28.9%
- Total debt
- +142.7%
Quarter to September 2026, against a year earlier
Follow ABT
Alert me
Abbott Laboratories (ABT) Return on assets
Abbott Laboratories's return on assets over the twelve months to 30 September 2026 was 0.00%, down 7.8 percentage points from fiscal 2025 (7.76%). Over the past ten years it has ranged from 0.74% (fiscal 2017) to 17.3% (fiscal 2024); the current reading is higher than 64% of that period. That is above the Medical Devices industry median of −17.3% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 7.76% | (9.57) |
| FY2024 | 17.3% | 9.58 |
| FY2023 | 7.75% | (1.52) |
| FY2022 | 9.27% | (0.30) |
| FY2021 | 9.57% | 3.17 |
| FY2020 | 6.40% | 0.94 |
| FY2019 | 5.46% | 2.16 |
| FY2018 | 3.30% | 2.56 |
| FY2017 | 0.74% | (2.24) |
| FY2016 | 2.98% | (7.75) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| DXCM DexCom, Inc. compare | 14.4% |
| BSX Boston Scientific Corporation compare | 7.94% |
| STE STERIS plc compare | 7.83% |
| SYK Stryker Corporation compare | 7.68% |
| EW Edwards Lifesciences Corporation compare | 7.45% |
| GEHC GE HealthCare Technologies Inc. compare | 5.78% |
| MDT Medtronic PLC compare | 5.68% |
| PHG Koninklijke Philips N.V. compare | 3.49% |
| ABT Abbott Laboratories | 0.00% |
| Medical Devices industry median | −17.3% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on ABT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement